Skip to main content

STARD1 Y SAB EN LA ENFERMEDAD ALCOHOLICA HUMANA: VALIDACION EN UN MODELO MURINO CON HIGADO HUMANIZADO

PID2019-111669RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]

  • Fernández-Checa, José C.
  • Bagnaninchi, Pierre
  • Ye, Hui
  • Sancho-Bru, Pau
  • Falcón-Pérez, Juan M.
  • Royo, Félix
  • García-Ruiz, Carmen
  • Konu, Ozlen
  • Miranda, Joana
  • Lunov, Oleg
  • Dejneka, Alexandr
  • Elfick, Alistair
  • McDonald, Alison
  • Sullivan, Gareth J.
  • Aithal, Guruprasad P.
  • Lucena, M. Isabel
  • Andrade, Raúl J.
  • Fromenty, Bernard
  • Kranendonk, Michel
  • Cubero, Francisco Javier
  • Nelson, Leonard J.
Drug-induced liver injury (DILI) is a major cause of acute liver failure (ALF) and one of the leading indications for liver transplantation in Western societies. Given the wide use of both prescribed and over the counter drugs, DILI has become a major health issue for which there is a pressing need to find novel and effective therapies. Although significant progress has been made in understanding the molecular mechanisms underlying DILI, our incomplete knowledge of its pathogenesis and inability to predict DILI is largely due to both discordance between human and animal DILI in preclinical drug development and a lack of models that faithfully recapitulate complex pathophysiological features of human DILI. This is exemplified by the hepatotoxicity of acetaminophen (APAP) overdose, a major cause of ALF because of its extensive worldwide use as an analgesic. Despite intensive efforts utilising current animal and in vitro models, the mechanisms involved in the hepatotoxicity of APAP are still not fully understood. In this expert Consensus Statement, which is endorsed by the European Drug-Induced Liver Injury Network, we aim to facilitate and outline clinically impactful discoveries by detailing the requirements for more realistic human-based systems to assess hepatotoxicity and guide future drug safety testing. We present novel insights and discuss major players in APAP pathophysiology, and describe emerging in vitro and in vivo pre-clinical models, as well as advanced imaging and in silico technologies, which may improve prediction of clinical outcomes of DILI., This work is supported by COST Action CA17112, www.cost.eu. LJN is supported by AMMF 2018/117; with support from grants - BBSRC (Grant BB/L023687/1), EPSRC (IAA Grant PIII013). MK and JM were partly funded by the Fundação para a Ciencia e a Tecnologia (FCT, Portugal), through grants UID/BIM/0009/2020 for the Research Center for Toxicogenomics and Human Health-(ToxOmics) and PTDC/MED-TOX/29183/2017 and UIDB/04138/2020 for the iMed.ULisboa, respectively. OK is supported by the Scientific and Technological Research Council of Turkey (TUBITAK 116Z388) and COST Action CA17112. PSB is supported by the Fondo de Investigación Sanitaria Carlos III, cofinanced by the Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, “Una manera de hacer Europa” (FIS PI20/00765, PI17/00673), DTS18/00088 and Miguel Servet (CPII16/00041); AGAUR 2019_PROD_00055; NIHAAA 1U01AA026972-01. OL is supported by the Czech Ministry of Education, Youth and Sports (Project No. LTC19040). FJC is supported by the MINECO Retos SAF2016-78711 EXOHEP-CM S2017/BMD-3727, NanoLiver-CM Y2018/NMT-4949, ERAB Ref. EA 18/14, AMMF 2018/117, UCM-25-2019 and COST Action CA17112, RYC-2014-15242 and Gilead Liver Research 2018. JCFC and CGR are supported from grants and SAF2017-85877R, PID2019-111669RB-100 the CIBEREHD; the center grant P50AA011999 Southern California Research Center for ALPD and Cirrhosis funded by NIAAA/NIH; as well as support from AGAUR of the Generalitat de Catalunya SGR-2017-1112, the “ER stress-mitochondrial cholesterol axis in obesity-associated insulin resistance and comorbidities”-Ayudas FUNDACION BBVA and the Red Nacional 2018-102799-T de Enfermedades Metabólicas y Cáncer, Project 201916/31 from Fundació Marato TV3, and European Cooperation in Science & Technology (COST) ACTION CA17112 Prospective European Drug-Induced Liver Injury Network, www.cost.eu. GJS was partially supported by the Research Council of Norway through its Centres of Excellence funding scheme (Project number 262613).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Hypoxia signaling and cholesterol/steroidogenic acute regulatory protein 1 axis: interplay and role in alcohol and non-alcohol-related liver diseases

  • Torres, Sandra
  • Fernández-Checa, José C.
  • García-Ruiz, Carmen
Metabolic zonation in the liver carries out the maintenance of organ and body homeostasis. Hypoxia is an inherent physiological feature of the liver and contributes to the zonal properties of the hepatic parenchyma. As a master regulator of hypoxia, the transcription factor hypoxia-inducing factor (HIF) is stabilized primarily by oxygen availability, and it is thought to contribute to steatohepatitis due to alcohol-related (ASH) and non-alcohol-related liver disease (NASH). Cholesterol has emerged as an important player in both diseases, and hypoxia increases hepatic cholesterol levels. Steroidogenic acute regulatory protein 1 (STARD1) is a mitochondrial outer membrane protein that transfers cholesterol to mitochondrial inner membrane for metabolic processing and acts as the rate-limiting step in the alternative pathway of bile acid synthesis in hepatocytes. STARD1 expression increases in ASH and NASH and determines the accumulation of cholesterol in mitochondria, which impacts the physico-chemical mitochondrial membranes properties and as a consequence impairs the activity of specific mitochondrial solute carriers, such as the 2-oxoglutarate carrier (2-OGC), limiting the exchange between cytosolic glutathione and mitochondrial 2-oxoglutarate (2-OG). Although HIF-1 is stabilized in hypoxia largely due to the requirement of prolylhydroxylases (PHDs) for oxygen to signal HIF degradation, PHDs are also dependent on 2-OG, and therefore it is conceivable that impairment of 2-OGC by STARD1-mediated cholesterol accumulation may contribute to HIF-1 stabilization due in part to decreased availability of cytosolic 2-OG. In this perspective, this review explores the interplay between HIF-1 stabilization and STARD1 induction and the potential contribution of this functional relationship to ASH and NASH., We acknowledge the support from the grants PID2019-111669RB-I00 and PID2020-115055RB-I00 from Plan Nacional de I+D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; the center grant P50AA011999 Southern California Research Center for ALPD and Cirrhosis funded by NIAAA/NIH; as well as support from AGAUR of the Generalitat de Catalunya SGR-2017-1112, European Cooperation in Science & Technology (COST) ACTION CA17112 Prospective European Drug-Induced Liver Injury Network, and the Red Nacional 2018-102799-T de Enfermedades Metabólicas y Cáncer and the Project 201916/31 ‘Contribution of mitochondrial oxysterol and bile acid metabolism to liver carcinogenesis’ 2019 by Fundació Marató TV3.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Role of Oxidative Stress in Liver Disorders

  • Conde de la Rosa, Laura
  • Goicoechea, Leire
  • Torres, Sandra
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
Oxygen is vital for life as it is required for many different enzymatic reactions involved in intermediate metabolism and xenobiotic biotransformation. Moreover, oxygen consumption in the electron transport chain of mitochondria is used to drive the synthesis of ATP to meet the energetic demands of cells. However, toxic free radicals are generated as byproducts of molecular oxygen consumption. Oxidative stress ensues not only when the production of reactive oxygen species (ROS) exceeds the endogenous antioxidant defense mechanism of cells, but it can also occur as a consequence of an unbalance between antioxidant strategies. Given the important role of hepatocytes in the biotransformation and metabolism of xenobiotics, ROS production represents a critical event in liver physiology, and increasing evidence suggests that oxidative stress contributes to the development of many liver diseases. The present review, which is part of the special issue “Oxidant stress in Liver Diseases”, aims to provide an overview of the sources and targets of ROS in different liver diseases and highlights the pivotal role of oxidative stress in cell death. In addition, current antioxidant therapies as treatment options for such disorders and their limitations for future trial design are discussed., We acknowledge the support from grants PID2019-111669RB-100 and PID2020-115055RBI00 from Plan Nacional de I+D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; the center grant P50AA011999 Southern California Research Center for ALPD and Cirrhosis funded by NIAAA/NIH; as well as support from AGAUR of the Generalitat de Catalunya SGR-2017- 1112, European Cooperation in Science & Technology (COST) ACTION CA17112, Prospective European Drug- Induced Liver Injury Network, the 2018-102799-T “Enfermedades Metabólicas y Cáncer” from the Red Nacional of the Spanish Health Ministry and the Project 201916/31 Contribution of mitochondrial oxysterol and bile acid metabolism to liver carcinogenesis 2019 by Fundació Marató TV3.